HC Wainwright restated their neutral rating on shares of Panbela Therapeutics (NASDAQ:PBLA – Free Report) in a research note released on Thursday morning, Benzinga reports. HC Wainwright also issued estimates for Panbela Therapeutics’ Q3 2024 earnings at ($1.63) EPS, Q4 2024 earnings at ($1.61) EPS, FY2024 earnings at ($6.76) EPS, FY2025 earnings at ($4.44) EPS, FY2026 earnings at ($3.43) EPS, FY2027 earnings at ($1.55) EPS and FY2028 earnings at $0.01 EPS.
Panbela Therapeutics Price Performance
Shares of NASDAQ PBLA opened at $0.37 on Thursday. Panbela Therapeutics has a 1-year low of $0.30 and a 1-year high of $38.00. The firm has a market capitalization of $1.28 million, a PE ratio of 0.00 and a beta of 1.58. The business’s fifty day moving average price is $0.37 and its two-hundred day moving average price is $0.58.
Panbela Therapeutics Company Profile
Read More
- Five stocks we like better than Panbela Therapeutics
- What is the FTSE 100 index?
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Investing in Commodities: What Are They? How to Invest in Them
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What is a buyback in stocks? A comprehensive guide for investors
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.